Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched
A phase III trial is underway to evaluate the efficacy and safety of MEDI5752 in combination with standard chemotherapy in patients with unresectable pleural mesothelioma.
Asset / Drug
Drug and asset intelligence for MEDI5752 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.